Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
No causal association between elevated red cell distribution width and pulmonary arterial hypertension was established.
Pulmonary arterial hypertension with systemic sclerosis associated-survival improved over time among patients aged 70 years or younger, but not among the elderly.
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
Researchers evaluated whether cardiopulmonary exercise testing could improve the performance of the DETECT screening approach in systemic sclerosis-related pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
This study assessed improvement in pulmonary vascular resistance and cardiac index in patients with pulmonary arterial hypertension who rapidly inhale iloprost 2.5 ug via the Breelib™ nebulizer.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
The FDA has approved the supplemental NDA for Orenitram extended-release tablets for the treatment of PAH to delay disease progression, in addition to improving exercise capacity.
